• "Quality of Life in Epidermolysis Bullosa" and "Epidermolysis Bullosa Burden of Disease": Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires
• A Case of Dystrophic Epidermolysis Bullosa Responding to Oral Corticosteroids
• A case of epidermolysis bullosa pruriginosa with a COL7A1 gene mutation successfully treated with upadacitinib
• A case of Neonatal generalized atrophic benign epidermolysis bullosa due to variants of COL17A1 gene
• A rare serpiginous pattern of epidermolysis bullosa pruriginosa
• A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa
• Advancing Care in Epidermolysis Bullosa: Insights from Qualitative Research
• Anesthesia management for patients with congenital epidermolysis bullosa: A challenge case report for the anesthesiologist
• Assessing the Application of Large Language Models in Generating Dermatologic Patient Education Materials According to Reading Level: Qualitative Study
• Atypical manifestations of hemangiomas in epidermolysis bullosa
• Cancer-associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma
• Characterization of novel therapies for epidermolysis bullosa in clinical development: a cross-sectional analysis
• Chondroitin sulfate proteoglycan 4 (CSPG4) increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying TGFbeta signaling
• Citrullinated Histone H3, a Marker for Neutrophil Extracellular Traps, Is Associated with Poor Prognosis in Cutaneous Squamous Cell Carcinoma Developing in Patients with Recessive Dystrophic Epidermolysis Bullosa
• Clinical and biological perspectives on non-canonical esophageal squamous cell carcinoma in rare subtypes
• Clinical phenotype of the PIK3R1-related vascular overgrowth syndrome
• Congenital nail abnormalities
• Congenital pyloric atresia associated with epidermolysis bullosa junctionalis: a novel lethal variant
• Correction to: Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization
• Corrigendum: The impact, perceptions and needs of parents of children with epidermolysis bullosa
• Creation and characterization of novel rat model for recessive dystrophic epidermolysis bullosa: Frameshift mutation of the Col7a1 gene leads to severe blistered phenotype
• Descriptive Study of the Clinical and Molecular Features of Epidermolysis Bullosa Patients in a Romanian European Reference Network-Skin Affiliated Reference Center
• Diagnostic Challenges in a Family with Dominant Dystrophic Epidermolysis Bullosa and Isolated Hereditary Nail Disorder: Paternal Gonosomal Mosaicism for COL7A1 Mutation and Maternal RSPO4 Variant
• Discovering the pathogenesis of autoimmune inflammation
• Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
• Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa
• Dystrophic Epidermolysis Bullosa (DEB): How Can Pregnancy Alter the Course of This Rare Disease? An Updated Literature Review on Obstetrical Management with an Additional Italian Experience
• Dystrophic epidermolysis bullosa characterized by mucosal lesions in a Chinese familial case with a novel compound heterozygous mutation of COL7A1
• Dystrophic epidermolysis bullosa: from disease biology to biologic therapy
• Early use of nasogastric tubes may lead to serious oesophageal complications in patients with severe epidermolysis bullosa
• Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study
• Emerging DNA & RNA editing strategies for the treatment of epidermolysis bullosa
• Endoscopic balloon dilation of esophageal stricture in dystrophic epidermolysis bullosa patient: challenges faced and safety of procedure
• Epidemiological Characteristics of Inherited Epidermolysis Bullosa in an Eastern European Population
• Epidemiology of Epidermolysis Bullosa in Chile
• Epidermolysis Bullosa in Spain: A Qualitative Analysis of Its Social Impact on Families With Diagnosed Minors
• Epidermolysis Bullosa Pruriginosa treated with baricitinib: A case report
• Epidermolysis Bullosa Pruriginosa Treated With Upadacitinib
• Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial
• Evidence of Cannabidiol Effectiveness Associated or Not with Tetrahydrocannabinol in Topical Administration: A Scope Review
• Expanding the Clinical Phenotype of PLECTIN-Related Plectinopathies
• Experience of dupilumab treatment in inherited epidermolysis bullosa: a short series
• Exploring the Impact of Epidermolysis Bullosa on Parents and Caregivers: A Cross-Cultural Validation of the Epidermolysis Bullosa Burden of Disease Questionnaire
• Facing the complex challenges of people with epidermolysis bullosa in Austria: a mixed methods study on burdens and helpful practices
• Functional Genotype-Phenotype Associations in Recessive Dystrophic Epidermolysis Bullosa
• Gene expression landscape of cutaneous squamous cell carcinoma progression
• Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa
• Highlights of Gene and Cell Therapy for Epidermolysis Bullosa and Ichthyosis
• Highly efficient CRISPR/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa
• Histological and molecular restoration of type VII collagen in Recessive dystrophic epidermolysis bullosa mouse skin by topical injection of keratinocyte-like cells differentiated from human adipose-derived mesenchymal stromal cells
• Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa
• Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa
• Identifying epidermolysis bullosa subtypes through immune antigenic mapping in Turkish patients
• Increased healthcare burden and comorbidity risks of pediatric patients with dystrophic epidermolysis bullosa: Analysis of Nationwide Emergency Department Sample 2015-2019
• Infant with a hereditary blistering disorder: an interesting case in the NICU
• Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita
• Involvement of Kindlin-1 in cutaneous squamous cell carcinoma
• Journal Club: Recent therapeutic developments in epidermolysis bullosa
• Junctional Epidermolysis Bullosa Linked to Homozygous Mutation in LAMC2 Gene: A Case Report With Eosinophil-Rich Inflammatory Infiltrate
• KRT5 in-frame deletion in a family of German Shepherd dogs with split paw pad disease resembling localized epidermolysis bullosa simplex in human patients
• LAMB3: Central role and clinical significance in neoplastic and non-neoplastic diseases
• Learning to Say Goodbye
• Lessons to Learn About the Misdiagnosis of a Rare Case in China: Bart Syndrome or Carmi Syndrome?
• Lethal Carmi syndrome (junctional epidermolysis bullosa-pyloric atresia) with a novel and recurrent compound integrin beta 4 heterozygous mutation: A case report
• Management of pain in the inpatient and non-surgical outpatient dermatology settings: A narrative review
• Mini-implant assisted palate expansion and digital design in junctional epidermolysis bullosa and amelogenesis imperfecta: Case report
• Molecular profiling of an Indian EB cohort - a single centre experience
• Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications
• Navigating the diagnostic journey of epidermolysis bullosa - a qualitative study on the lived experiences and needs of parents and patients
• Novel variant c.7795-1G>A of COL7A1 gene in a 12-month-old female child with recessive dystrophic epidermolysis bullosa treated with dupilumab
• Of LAMA3 and LAMB3: A novel gene therapy for epidermolysis bullosa
• Online, home-based dystrophic epidermolysis bullosa registry
• Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa
• Practical guide for epidermolysis bullosa management in the first 4 weeks of life
• Presentation of Rare Phenotypes Associated with the <em>FKBP10</em> Gene
• Reconstruction with free jejunal flap in dystrophic epidermolysis bullosa complicated with hypopharyngeal cancer: A case report
• Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials
• Renal Amyloidosis in a Child with Recessive Dystrophic Epidermolysis Bullosa Due to a Novel Variant in COL7A1 Gene
• Review: the spectrum of antimicrobial resistance in bacteria isolated from wounds of patients with epidermolysis bullosa
• Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review
• Scarring alopecia and nail loss in a patient with epidermolysis bullosa acquisita
• Small fiber neuropathy in epidermolysis bullosa simplex
• Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa
• State-of-the-art diagnosis of autoimmune blistering diseases
• Stopping a runaway train: targeting fibrosis in recessive dystrophic epidermolysis bullosa
• Syndromic epidermolysis bullosa simplex subtype due to mutations in the KLHL24 gene: series of case reports in Russian families
• Systematic review on antipruritic therapies for patients with Epidermolysis bullosa
• The impact, perceptions and needs of parents of children with epidermolysis bullosa
• Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases
• Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa
• Toxic Flexural Epidermolysis in hospitalized patients
• Treatment of Epidermolysis bullosa acquisita with dupilumab
• Treatment of Epidermolysis Bullosa and Future Directions: A Review
• Twin prime editing mediated exon skipping/reinsertion for restored collagen VII expression in recessive dystrophic epidermolysis bullosa
• Two sisters with recessive dystrophic epidermolysis bullosa caused by novel variants in COL7A1
• Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa
• Unusual presentation of cutaneous myiasis in the knee: case report
• Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study
• Verrucous plaque on the foot in a 12-year-old boy with epidermolysis bullosa
• Wound behavior in dystrophic epidermolysis bullosa: A retrospective natural history case series